[Clinical study of the NCC-ST-439 EIA kit using serum from patients with various types of cancer and benign disease (2)].
The positive rates for NCC-ST-439 in cases where other tumor markers were negative were 16.8% for CA19-9-negative cancer cases and 23.5% for CEA-negative cancer cases. The positive rates obtained using a combination of these three markers were 86% for pancreatic and cholangiocarcinomas, and at least 65% for hepatocellular, rectal and colonic and mammary carcinomas. The following combinations of tumor markers were the best from the standpoint of diagnostic efficiency: NCC-ST-439 + CA19-9 for pancreatic carcinoma, NCC-ST-439 + AFP for hepatocellular carcinoma, and NCC-ST-439 + CEA for rectal and colonic carcinoma. In cases which were positive preoperatively, 83.3% became negative after curative surgery, which reflected the clinical course very well. These results indicate that NCC-ST-439 improves the diagnostic rate in combination with other tumor markers because of its high specificity, and it was evaluated as useful for the monitoring of therapeutic effects.
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis*; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D013274:Stomach Neoplasms / Q000276:immunology; D000509:alpha-Fetoproteins / Q000032:analysis
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins; D011933:Reagent Kits, Diagnostic; D000509:alpha-Fetoproteins